<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Nodify XL2 Test

Help identify patients with likely benign lung nodules

Nodify XL2™ testing supports clinical decision-making so physicians can more confidently identify patients with lung nodules who have a reduced risk of malignancy and may avoid unnecessary invasive procedures.

Nodify XL2™ testing helps decipher if a lung nodule is likely benign, instilling confidence in the recommended path forward for both physicians and patients.

Order Nodify XL2

Which patients are right for Nodify XL2 testing?

The Nodify XL2 test is intended for patients with incidental lung nodules:

Clinically Validated Results

  • The Nodify XL2 test measures two proteins associated with an inflammatory response to lung cancer to help physicians identify nodules that are likely benign2.
  • In the PANOPTIC study2, Nodify XL2 demonstrated a median test performance of 97% sensitivity with a 98% negative predictive value (NPV).


The Nodify XL2™ blood test helps direct next steps in lung nodule management

Dr. Susan Garwood from TriStar Centennial Medical Center discusses lung nodule management and the Nodify XL2™ test


There is no out of pocket expense for Medicaid and covered Medicare patients for Nodify XL2™ testing

Learn more

Financial Assistance

We understand the financial stresses that health issues can place on patients. We have created a financial assistance program for patient with financial responsibility to assist in providing affordable care.

To learn more about our financial assistance program, please contact our Customer Care team at 1.866.432.5930.

Contact Us

Interested in ordering a Nodify LungTM test kit?​

The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT™ and the Nodify XL2™ proteomic tests.


Get in touch

Contact Us

Data Library

Discover More

1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.

2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.